ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Lutathera CA 370 MBq/ml Infusionslösung:Novartis Pharma Schweiz AG
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
V10XX04 - Lutetium (177lu) OxodotreotideATC-DDD Version 2016. Source: WHO
V - Various
 

This group comprises many different types of drugs, and assigning DDDs are difficult. Very few DDDs are assigned in this group.

V10 - Therapeutic Radiopharmaceuticals

Radiopharmaceuticals for therapeutic use are classified in this group, while radiopharmaceuticals for diagnostic use are classified in V09 - Diagnostic radiopharmaceuticals. Radiopharmaceuticals for cancer treatment are classified in V10X.
See comments to V09.

V10X - Other Therapeutic Radiopharmaceuticals

This group contains various therapeutic radiopharmaceuticals which cannot be classified in the preceding groups.

V10XX - Various Therapeutic Radiopharmaceuticals

Radiopharmaceuticals for cancer treatment and various therapeutic radiopharmaceuticals which cannot be classified in the preceding groups are classified here.

V10XX04 - Lutetium (177lu) Oxodotreotide
2024 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home